Data / Form D filings / NantBio, Inc.
NantBio, Inc.: Form D filings
NantBio, Inc., a biotechnology company in El Segundo, CA, filed 6 Form D notices with the SEC between 2014 and 2023. The latest, on November 13, 2023, reports $75.1 million sold of a $75.1 million offering to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 450 Duley Road, El Segundo, CA, 90245
- Phone
- (310) 853-7888
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1608318
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2023 | New notice | $75,073,925 | $75,073,925 | 6 | Nov 8, 2023 | sec.gov | |
| Jun 2, 2015 | Amendment | $10,000,000 | $10,000,000 | 1 | Apr 29, 2015 | sec.gov | |
| May 12, 2015 | New notice | $100,000,000 | $100,000,000 | 1 | Apr 29, 2015 | sec.gov | |
| Feb 6, 2015 | New notice | $45,000,000 | $45,000,000 | 1 | Jul 9, 2014 | sec.gov | |
| Oct 30, 2014 | New notice | $100,000,000 | $25,000,000 | $75,000,000 | 1 | Oct 24, 2014 | sec.gov |
| May 16, 2014 | New notice | $25,000,000 | $25,000,000 | 1 | Jan 2, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Douglas Reed Maughan | Director | |
| James Banaag | Executive Officer | |
| Charles Kenworthy | Executive Officer, Director | |
| Patrick Soon-Shiong | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Nov 13, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what NantBio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.